Delivery Order SPE2DB22D3016-SPE2DB25FBDN9
- Not listed
- The Defense Logistics Agency awarded a $1,961.76 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes, with a completion date of September 4, 2025. This non-competitive delivery order represents a small-value transaction under AmerisourceBergen's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a $1,954.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes, with an ultimate completion date of August 21, 2025. This non-set-aside competitive award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes valued at $9,034.57 under a firm fixed price contract type. The award was made on July 18, 2025, with an ultimate completion date of July 21, 2025, and represents a competitively awarded, non-set-aside procurement. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company serves as a major...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,343.67 delivery order for ENGERIX-B 20 MCG/ML vaccine syringes, with an ultimate completion date of May 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes valued at $4,177.19 on July 21, 2025, with completion expected by July 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $1,030.56 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes. This non-competitive delivery order, issued on June 2, 2025, with an ultimate completion date of June 3, 2025, represents a firm fixed price transaction executed through the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded a $1,837.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 mcg/mL vaccine syringes on August 7, 2025, with an ultimate completion date of August 8, 2025. This non-set-aside contract was performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes valued at $1,583.34 with a firm fixed price structure. This non-competitive delivery order, issued on September 17, 2025, with ultimate completion by September 18, 2025, represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply framework. The award utilizes no set-aside designation and will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes, with a contract ceiling value of $1,387.80. This firm fixed-price delivery order, issued on June 2, 2025, with a completion date of June 3, 2025, was competitively awarded without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $3,312.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes, with an ultimate completion date of September 8, 2025. This non-set-aside award represents a competitively awarded transaction under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical supply vendor...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBDN9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,030.56 for ENGERIX-B 20 MCG/ML vaccine syringes, with a completion deadline of July 31, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's broader federal contract portfolio supporting military and veteran healthcare systems. This delivery order falls under AmerisourceBergen's significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. The parent IDC enables AmerisourceBergen to supply a vast range of pharmaceutical products and medical supplies, including vaccines, specialty medications, and generic drugs, supporting Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide. The DLA's Pharmaceutical Prime Vendor Global Program Generation V initiative, under which this IDC operates, plans multiple regional awards to ensure diverse supplier participation while maintaining critical medical supply chain capabilities for military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 7/30/25 |